EQT X to Acquire Corza Biosurgery (TachoSil) from Corza Medical

July 10, 2026

EQT X has agreed to acquire Corza Biosurgery, the biosurgery business unit centered on the TachoSil biologic hemostat and tissue-sealing patch, from Corza Medical. The deal is expected to close in Q4 2026, with EQT planning to invest in commercial acceleration, innovation, and geographic/indication expansion.

Buyers
EQT X, EQT
Targets
Corza Biosurgery, Corza Medical's Biosurgery business unit (including TachoSil product portfolio)
Sellers
Corza Medical, Corza Medical's Biosurgery business unit
Location
Upper Austria, Austria
Transaction Type
Divestiture

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →